Leerink Partners Upgrades Myriad Genetics to Outperform, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Puneet Souda upgraded Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and increased the price target from $25 to $35.
May 08, 2024 | 5:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners upgraded Myriad Genetics to Outperform and raised the price target to $35.
Upgrades by analysts, especially with a significant increase in price target, typically lead to positive short-term price movements as market sentiment improves. The upgrade from Market Perform to Outperform suggests a strong confidence in the company's future performance, potentially leading to increased investor interest and stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100